NERV Company Profile and Key Details

Minerva Neurosciences, Inc. has 43.27 million shares outstanding. The public float is 3.98 million shares, elevated short interest at 1.07% of float. This equals 432.78 thousand shares. The short ratio is 4.55 days. Institutional investors hold 70.84% of the float. Insiders own 3.6%. De Rubertis Francesco holds 4.49 million shares, Ollier Michele has 4.49 million shares and Index Venture Associates III Ltd has 3.90 million shares.

Short-term trend indicators are bearishly aligned (SMA20 10.28%, SMA50 30.76%, SMA200 102.56%). The stock’s 14-day RSI is 67.11 (firm momentum), while the ATR of 0.5 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -50.0% below its high and over 441.74% above its low. Average 10-day trading volume of 89.39 thousand shares is below the 3-month average of 230.79 thousand, indicating normal recent market interest.

The latest quarter delivered EPS of -$0.17. The next quarter is forecast at -$0.30. Next year's EPS is expected at $18.78. Analyst sentiment is neutral. Analyst rating data shows there are 1 Strong Buy ratings, 0 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $14.00 to $4.00. The high target offers 148.67% upside. The low target suggests -28.95% downside. The mean target is $8.33. This offers 47.96% upside. Minerva Neurosciences, Inc. earnings surprise history is a mixed track record. The quarter that ended May 05, 2026, missed forecasts by 30.77%. The prior quarter beat by 481.82%. Over the last six quarters, Apple has recorded several small beats. These include -46.67% in February 25, 2025.

Minerva Neurosciences, Inc. (NASDAQ:NERV) closed at $5.62 USD, losing -$0.01 (-0.18%) from the previous close of $5.63. The stock is currently mid-range between its 52-week high and low $1.30 and $12.46. With a market capitalization of about $39.30 million, Minerva Neurosciences, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.10). Key stats such as the average daily volume over the past year has been around 251.91 thousand shares, volume is running light vs its 52-week average. Headquartered in Burlington, MA, Minerva Neurosciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Remy Luthringer, the company employs approximately 8 people and listed since July 01, 2014. Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases.

Minerva Neurosciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.05. This means the shares are trading above this model’s fair value.

Minerva Neurosciences, Inc. trades at a P/E ratio of -0.61, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -0.99 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.01, also above market averages.

Our AI price prediction model suggests that Minerva Neurosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.13%, with price expected at $5.51 by May 25, 2026, within a range of $4.64 to $6.38 3-Month Outlook: Projected fall of -28.77%, reaching $4.01 by August 07, 2026, with a range of $3.70 to $4.33. 1-Year Outlook: Projected gain of 406.39%, with price at $28.51 by May 11, 2027, within a range of $30.50 to $32.29.

Minerva Neurosciences, Inc. (NASDAQ:NERV) shares are flat 8.71% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Minerva Neurosciences, Inc. trading at a premium to the broader market with a P/E of -0.61. Analyst sentiment is cautious, with the majority of ratings in Market Outperform territory and a mean price target of $11.13, suggesting 97.69% upside. Our AI forecast model points to short-term weakness (-2.13% over two weeks), a medium-term fall (-28.77% over three months), and a longer-term gain (406.39% over one year), with expected trading ranges indicating moderate volatility.